SOFIE Inc, a Theranostics company, has signed a global license with University Clinic Heidelberg for a class of molecular targeted diagnostics and radiotherapeutics that are aimed at identifying and breaking down cancer associated fibroblasts in tumour stroma and irradiate nearby cancer cells, it was reported on Friday.
The license includes the small molecule inhibitors of fibroblast activation-protein (FAP) inhibitors that can be named alternatively with different radioisotopes; those for diagnostic imaging to identify patients whose tumours contain fibroblast activation-protein inhibitors with high expression of fibroblast activation-protein inhibitors, and those for radiotherapeutic treatment of these patients.
More than 200 patients were imaged at the University Clinic Heidelberg, while five other academic centres in Germany investigating patients with a wide range of cancers. Moreover, a small number of patients received compassionate care therapy on an individual patient basis at Heidelberg University Hospital and were analysed in an approved retrospective observational study.
Philipp Czernin, SOFIE's chief revenue officer, led the negotiations with University Clinic Heidelberg.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories